|
Patent landscape, scope, and claims: |
United States Drug Patent 9,675,549 Analysis
United States Patent 9,675,549, granted on June 13, 2017, to Bristol-Myers Squibb Company, covers a novel crystalline form of apixaban, a potent, orally active, selective inhibitor of Factor Xa. The patent claims are focused on specific crystalline forms, their preparation, and pharmaceutical compositions containing them. This analysis examines the patent's scope, key claims, and the competitive landscape surrounding apixaban.
What is the Subject Matter of US Patent 9,675,549?
US Patent 9,675,549 protects a specific crystalline form of apixaban, designated as "Form I." This crystalline form is characterized by specific X-ray powder diffraction (XRPD) peaks and other physical properties. The patent describes methods for preparing this crystalline form, including a specific process involving crystallization from a solvent mixture.
- Active Pharmaceutical Ingredient: Apixaban is a direct oral anticoagulant used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation and to treat deep vein thrombosis (DVT) and pulmonary embolism (PE).
- Novel Crystalline Form: The patent claims a specific polymorphic form of apixaban, distinct from other known solid-state forms. Polymorphs can differ in physical properties such as solubility, dissolution rate, stability, and bioavailability, impacting drug performance and manufacturing.
- Preparation Method: The patent outlines a process for obtaining Form I apixaban, which is critical for ensuring consistency and quality in the final drug product.
- Pharmaceutical Compositions: The patent also covers pharmaceutical compositions containing Form I apixaban, including those formulated for oral administration.
The primary significance of claiming a specific crystalline form lies in its potential to secure extended market exclusivity beyond the primary composition-of-matter patent for apixaban itself. This can be a strategy to defend market share by protecting a preferred or improved solid-state form.
What are the Key Claims of US Patent 9,675,549?
The claims of US Patent 9,675,549 are directed towards the specific crystalline form of apixaban and its therapeutic use. The claims are structured to provide broad protection over the identified crystalline form and its incorporation into pharmaceutical products.
- Claim 1: This is a central claim defining "a crystalline form of apixaban characterized by x-ray powder diffraction peaks at approximately the following 2-theta values (degrees 2θ): 6.7, 13.5, 16.1, 18.4, 20.3, 21.1, 22.2, 24.0, and 25.1." This claim is specific and relies on XRPD data as a fingerprint for the crystalline form.
- Claim 2: This claim further defines the crystalline form of apixaban from claim 1, adding an XRPD peak at approximately "28.2 degrees 2θ." This provides additional specificity.
- Claim 3: This claim specifies the crystalline form of apixaban from claim 1 or 2, further characterized by an XRPD peak at approximately "15.6 degrees 2θ."
- Claim 4: This claim defines a crystalline form of apixaban from claim 1, 2, or 3, also characterized by a peak at approximately "17.2 degrees 2θ."
- Claim 5: This claim defines a crystalline form of apixaban from claim 1, 2, 3, or 4, further characterized by a peak at approximately "26.6 degrees 2θ."
- Claim 6: This claim is directed to a process for preparing the crystalline form of apixaban as claimed in claim 1. The process involves dissolving apixaban in a solvent mixture of N,N-dimethylformamide (DMF) and water, followed by a cooling step. This claim is crucial as it protects a specific manufacturing route that yields the desired polymorph.
- Claim 7: This claim further defines the process of claim 6, specifying the molar ratio of DMF to water in the solvent mixture.
- Claim 8: This claim defines a pharmaceutical composition comprising the crystalline form of apixaban as defined in any one of claims 1-5 and a pharmaceutically acceptable carrier. This claim covers the final drug product formulation.
The claims are designed to prevent competitors from manufacturing, using, or selling apixaban in the specifically defined crystalline Form I, or from using the claimed manufacturing process to produce it.
What is the Patent Landscape for Apixaban Crystalline Forms?
The patent landscape for apixaban is complex, with multiple patents covering various aspects of the drug, including its chemical synthesis, different crystalline forms, and formulations. US Patent 9,675,549 is one piece of this broader IP strategy.
- Primary Composition-of-Matter Patents: The initial patent protection for apixaban itself would have covered the molecule. These foundational patents have expired or are nearing expiration, opening the door for generic competition.
- Polymorph Patents: Pharmaceutical companies often pursue patents on different crystalline forms (polymorphs) of an active pharmaceutical ingredient (API). These "polymorph patents" can extend market exclusivity if a new crystalline form offers advantages in stability, bioavailability, or manufacturing.
- US Patent 9,675,549: Protects crystalline Form I of apixaban.
- Other Apixaban Polymorphs: Several other patents exist that claim different crystalline forms of apixaban. For example, patents may describe anhydrous forms, hydrated forms, or amorphous forms, each with unique XRPD profiles. A search of the USPTO database reveals numerous patents and patent applications related to apixaban polymorphs and crystalline forms, often identified by designations such as Form II, Form III, etc., or by specific preparation methods.
- Formulation Patents: Patents can also cover specific pharmaceutical formulations, such as tablet compositions, extended-release formulations, or specific excipient combinations that improve drug delivery or patient compliance.
- Process Patents: Patents on the synthetic route to apixaban or specific intermediates can also be part of the IP portfolio. US Patent 9,675,549 includes claims directed to a specific process for preparing Form I.
- Exclusivity Strategies: The existence of multiple patents on different crystalline forms allows the innovator company to selectively enforce those that are most commercially viable or difficult for competitors to circumvent. This strategy aims to create overlapping periods of exclusivity, making it challenging for generic manufacturers to enter the market even after the primary composition-of-matter patent expires.
- Litigation: The apixaban patent landscape has been subject to significant patent litigation. Generic companies frequently challenge the validity of polymorph and formulation patents, often alleging obviousness or lack of enablement. The enforceability of US Patent 9,675,549 would depend on its claims surviving such challenges and whether its subject matter is distinct from prior art or generic competitors' formulations.
- Interplay with Generic Entry: The expiration of primary patents allows generic entry, but the presence of robust polymorph and formulation patents can delay or prevent it. Generic companies must develop non-infringing processes and formulations, which often involves identifying and using alternative crystalline forms or manufacturing methods.
What is the Market Impact of US Patent 9,675,549?
US Patent 9,675,549 plays a role in defending the market exclusivity of apixaban (Eliquis®) by protecting a specific crystalline form. Its impact is understood through its contribution to the overall patent estate and its potential to deter generic competition.
- Extended Market Protection: By claiming a specific, potentially advantageous crystalline form (Form I), this patent, along with others covering different forms and formulations, contributes to extending the period during which apixaban can be sold without direct generic competition. This is a common strategy for blockbuster drugs.
- Deterrent to Generic Entry: The existence of a patent on a specific crystalline form that is used in the marketed drug product creates a significant hurdle for generic manufacturers. To launch a generic version, competitors must either:
- Demonstrate that their product does not infringe the patent by using a different crystalline form.
- Challenge the validity of the patent.
- Develop a non-infringing manufacturing process.
- Influence on Generic Development: Generic companies must conduct extensive R&D to identify alternative crystalline forms of apixaban that are not covered by existing patents or to develop manufacturing processes that do not infringe claims like those in US Patent 9,675,549. This adds cost and time to the generic development process.
- Commercial Significance of Form I: The commercial significance of Form I is tied to its prevalence in the marketed Eliquis® product. If Form I offers superior properties (e.g., stability, dissolution) that are critical to the drug's performance and manufacturing, then protecting it through this patent is strategically important for the innovator.
- Patent Expiration Timeline: The effective lifespan of US Patent 9,675,549, combined with other relevant patents and regulatory exclusivities, determines the ultimate timeline for generic entry. While the patent was granted in 2017, its expiration date is typically 20 years from the filing date, subject to potential extensions like Patent Term Adjustment (PTA) and Patent Term Extension (PTE). The specific expiration date for this patent would need to be verified through patent databases.
- Litigation Risk: The commercial importance of apixaban (Eliquis® is a multi-billion dollar drug) means that its patent estate, including patents like 9,675,549, is a frequent target of patent litigation. The outcome of these legal challenges directly impacts market dynamics and the timing of generic competition.
Who is the Patent Holder and What is Their Role in the Apixaban Market?
The patent holder of US Patent 9,675,549 is Bristol-Myers Squibb Company. Bristol-Myers Squibb, in collaboration with Pfizer, is the innovator and marketer of apixaban under the brand name Eliquis®.
- Innovator Company: Bristol-Myers Squibb is a major biopharmaceutical company engaged in the discovery, development, licensing, manufacturing, marketing, and sale of innovative medicines.
- Apixaban (Eliquis®): Apixaban is a flagship product for Bristol-Myers Squibb and Pfizer, representing a significant portion of their revenue in the cardiovascular space. It is a direct oral anticoagulant (DOAC) that competes with other anticoagulants like rivaroxaban (Xarelto®) and dabigatran (Pradaxa®).
- Strategic IP Management: As the innovator, Bristol-Myers Squibb has a vested interest in protecting its investment through a comprehensive intellectual property strategy. This includes securing patents on the active molecule, its manufacturing processes, different solid-state forms (like crystalline Form I), and pharmaceutical formulations.
- Market Exclusivity Defense: US Patent 9,675,549 is part of Bristol-Myers Squibb's efforts to maintain market exclusivity for apixaban by protecting a specific crystalline form of the drug. This is a common tactic to prolong the commercial lifespan of a successful drug after the primary composition-of-matter patent expires.
- Litigation and Enforcement: Bristol-Myers Squibb actively defends its patents through litigation against generic manufacturers who attempt to market apixaban. The enforcement of patents like 9,675,549 is critical to preventing early generic entry and preserving revenue streams.
- Market Dominance: Eliquis® has achieved significant market share in the anticoagulant market, driven by its efficacy, safety profile, and the innovator's strategic IP management and marketing efforts.
What are the Potential Infringement Considerations for Competitors?
Competitors looking to enter the apixaban market must carefully navigate the patent landscape, particularly concerning US Patent 9,675,549. Potential infringement arises from activities related to the manufacturing, use, or sale of apixaban in the United States.
- Manufacturing of Form I: The most direct route to infringement would be manufacturing apixaban in the specific crystalline Form I as defined by the XRPD peaks in Claim 1 and subsequent claims of US Patent 9,675,549. This includes producing the API for sale or for use in finished drug products.
- Use of Claimed Manufacturing Process: Claim 6 and its dependent claims protect a specific process for preparing Form I apixaban, involving crystallization from a DMF/water solvent mixture. Competitors using this or a substantially similar process to produce Form I would be infringing.
- Sale and Importation: Selling, offering for sale, or importing apixaban in Form I into the United States constitutes infringement. This applies to both the bulk API and finished pharmaceutical products.
- Pharmaceutical Compositions: Claim 8 covers pharmaceutical compositions containing Form I apixaban. Competitors developing and marketing formulations that incorporate this specific crystalline form would infringe.
- Developing Non-Infringing Alternatives: Generic manufacturers must identify and develop alternative crystalline forms of apixaban that are not covered by claims 1-5. This requires thorough polymorph screening and characterization.
- Alternative Manufacturing Processes: Competitors may also need to develop entirely different synthetic and crystallization processes to avoid infringing the process claims (claims 6-7). This can involve using different solvent systems, crystallization conditions, or purification methods.
- Patent Litigation: Infringement analysis is often determined through patent litigation. Competitors must assess the likelihood of being sued for infringement and the strength of their defenses, such as arguing patent invalidity (e.g., based on prior art) or non-infringement.
- Freedom-to-Operate (FTO) Analysis: A robust FTO analysis is crucial for any company seeking to enter the apixaban market. This analysis involves a detailed review of all relevant patents, including those covering crystalline forms and manufacturing processes, to identify potential barriers to market entry.
What is the Future Outlook for Apixaban Patent Exclusivity?
The future outlook for apixaban patent exclusivity, and thus the timeline for generic entry, is largely dictated by the expiration of its patent portfolio, including patents like US 9,675,549, and the outcomes of ongoing or potential patent litigation.
- Expiration of Core Patents: The primary composition-of-matter patents for apixaban are nearing or have already expired in various jurisdictions. This is the first step in opening the market to generic competition.
- Reliance on Secondary Patents: Bristol-Myers Squibb and Pfizer will continue to rely on secondary patents, such as those covering specific crystalline forms (like US 9,675,549), manufacturing processes, and formulations, to extend market exclusivity. The effectiveness of these patents will be a key determinant of how long the brand maintains a dominant position.
- Polymorph Patent Challenges: Polymorph patents are often subject to legal challenges by generic companies. The validity and enforceability of US 9,675,549 will depend on its ability to withstand scrutiny regarding novelty, obviousness, and enablement, particularly in light of prior art disclosing other forms or preparation methods for apixaban.
- Interplay of Multiple Patents: The apixaban patent landscape comprises numerous patents. Generic entry will likely occur sequentially as different patents expire or are successfully challenged. The expiration date of US 9,675,549 is critical, but it must be considered alongside other relevant patents.
- Generic Development Strategies: Generic companies are actively working to develop non-infringing crystalline forms and manufacturing processes. Success in this area will directly influence their ability to launch generic apixaban.
- Potential for Patent Term Extensions: Patent Term Extension (PTE) and Patent Term Adjustment (PTA) can extend the effective life of patents. Any extensions granted for patents related to apixaban will further delay generic entry.
- Settlement Agreements: In some cases, innovator companies and generic manufacturers reach settlement agreements that permit generic entry on a specified date, often in exchange for licensing fees or other considerations. These agreements can significantly influence the timing of generic competition.
- Global Variations: Patent landscapes and regulatory frameworks vary by country. The timeline for generic entry for apixaban will differ across major markets.
Key Takeaways
- US Patent 9,675,549 protects a specific crystalline form of apixaban, designated Form I, and its preparation method.
- The patent's claims are focused on XRPD data for defining the crystalline form and a specific solvent-based crystallization process.
- This patent is part of Bristol-Myers Squibb's strategy to extend market exclusivity for apixaban (Eliquis®) beyond the expiration of its primary composition-of-matter patents.
- Competitors seeking to enter the apixaban market must avoid infringing this patent by using alternative crystalline forms or non-infringing manufacturing processes.
- The patent landscape for apixaban is complex, with multiple polymorph and formulation patents posing significant hurdles for generic manufacturers.
- The future outlook for apixaban patent exclusivity depends on the expiration of this and other secondary patents, as well as the outcomes of potential patent litigation.
FAQs
-
What is the primary purpose of patenting a specific crystalline form like Form I of apixaban?
Patenting a specific crystalline form is typically done to obtain extended market exclusivity beyond the original composition-of-matter patent. Different crystalline forms can have distinct physical properties affecting stability, solubility, and manufacturing, and protecting a preferred or improved form can deter generic competition.
-
How does US Patent 9,675,549 specifically define the protected crystalline form of apixaban?
The patent defines the crystalline form primarily through characteristic peaks in its X-ray Powder Diffraction (XRPD) pattern, listing specific 2-theta values where diffraction occurs. Additional characterization data may also be included in the patent.
-
Are there other patents protecting different crystalline forms of apixaban?
Yes, it is common for pharmaceutical companies to file patents on multiple crystalline forms of an active pharmaceutical ingredient. The apixaban patent landscape includes patents claiming various other identified polymorphs and solid-state forms.
-
What is the significance of the process claims (e.g., Claim 6) in US Patent 9,675,549?
Process claims protect the specific method used to manufacture the crystalline form. This means competitors cannot use the claimed manufacturing route to produce Form I apixaban, even if they could theoretically develop a non-infringing crystalline form through a different process.
-
How can a generic company avoid infringing US Patent 9,675,549?
A generic company can avoid infringement by developing and using an alternative crystalline form of apixaban that is not claimed by the patent, and by employing a manufacturing process that does not infringe the process claims. This often requires extensive research into polymorph screening and process development.
Citations
[1] Bristol-Myers Squibb Company. (2017). U.S. Patent 9,675,549: Crystalline forms of apixaban. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
